Replies to post #1111 on Synaptogenix Inc (SNPX)

[SF Wolf]

I left this quote out of my previous post about Ray Dirks blog article:

I can't wait to see the data that the company will be releasing in five months, April 2017, from their 148 patient Phase II placebo controlled trial. Multi modal efficacy of bryostatin targeting PKC epsilon, versus everyone else's drugs, that are just trying to hit one target. It isn't even a fair fight. Neurotrope's bryostatin, if approved, is a blockbuster for one of the largest unmet medical needs in the world today.